Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy

IL-12 Is Required for Anti-OX40-Mediated CD4 T Cell Survival

(2014) C. E. Ruby et al.   JOURNAL OF IMMUNOLOGY

Macrophage Polarization in Bacterial Infections

(2014) M. Benoit et al.   JOURNAL OF IMMUNOLOGY

A Therapeutic OX40 Agonist Dynamically Alters Dendritic, Endothelial, and T Cell Subsets within the Established Tumor Microenvironment

(2010) A. D. Pardee et al.   CANCER RESEARCH

CTL Induction of Tumoricidal Nitric Oxide Production by Intratumoral Macrophages Is Critical for Tumor Elimination

(2010) R. D. V. Miguel et al.   JOURNAL OF IMMUNOLOGY

Thymic OX40 Expression Discriminates Cells Undergoing Strong Responses to Selection Ligands

(2009) M. Klinger et al.   JOURNAL OF IMMUNOLOGY

Impact of the TCR Signal on Regulatory T Cell Homeostasis, Function, and Trafficking

(2009) Joong Kyu Kim et al.   PLoS One

OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor

(2008) M. J. Gough et al.   CANCER RESEARCH

Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives

(2008) Paulo C. Rodríguez et al.   IMMUNOLOGICAL REVIEWS

Secretion of interferon-γ by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18

(2008) Laila Darwich et al.   IMMUNOLOGY

IFN-γ– and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers

(2008) Bin Zhang et al.   JOURNAL OF CLINICAL INVESTIGATION

IL-10 and the resolution of infections

(2007) CM Filippi et al.   JOURNAL OF PATHOLOGY